2024 Buyside View, plus Arnold Ventures’ impact: a BioCentury podcast

Market-creating catalysts. Biopharma’s most effective critic. Plus Gilead data and expected IPOs

Biotech investors are looking to catalysts that can create, or dramatically expand, commercial markets as they look ahead to a long-awaited recovery for industry. On the latest BioCentury This Week podcast, BioCentury’s editors assess the milestones on buysiders’ radar for 2024, including in areas such as obesity, pain and metabolic-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH).

They also discuss the influence of biopharma critic Arnold Ventures, a philanthropy that has reshaped the drug pricing public policy landscape.

Finally, the team touches on what’s next for Trodelvy sacituzumab govitecan after Gilead Sciences Inc. (NASDAQ:GILD) reported negative lung cancer data for the antibody-drug conjugate, and previews IPOs from  CG Oncology Inc. and ArriVent Biopharma Inc. that are expected to price this week.

For information on how to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact BioCentury at conferences@biocentury.com.